Education
About Us
Working with TipRanks
Follow Us
Prime Medicine, Inc. (PRME)
NASDAQ:PRME
PRME Stock Chart & Stats
$3.57
-$0.14(-4.27%)
At close: 4:00 PM EST
$3.57
-$0.14(-4.27%)
Day’s Range― - ―
52-Week Range$1.11 - $6.94
Previous CloseN/A
Volume144.88K
Average Volume (3M)3.08M
Market Cap
$644.42M
Enterprise Value$694.77M
Total Cash (Recent Filing)$208.43M
Total Debt (Recent Filing)$118.14M
Price to Earnings (P/E)―
Beta3.06
Next Earnings
Feb 27, 2026EPS Estimate
-0.25Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.32
Shares Outstanding180,510,650
10 Day Avg. Volume3,013,253
30 Day Avg. Volume3,081,425
Financial Highlights & Ratios
PEG Ratio0.07
Price to Book (P/B)2.26
Price to Sales (P/S)116.10
P/FCF Ratio-2.66
Enterprise Value/Market Cap1.08
Enterprise Value/Revenue116.24
Enterprise Value/Gross Profit-17.42
Enterprise Value/Ebitda-3.59
Forecast
1Y Price Target
$5.08Price Target Upside42.30% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering5
EPS Forecast (FY)-0.93
Revenue Forecast (FY)$17.20M
Bulls Say, Bears Say
Bulls Say
Clinical DevelopmentAnalysts view progress toward advancing Prime's preclinical gene editing programs into clinical trials as a catalyst that could renew investor confidence in curative technologies.
Preclinical EfficacyAnalysts highlight PM577's preclinical data showing efficient correction of Wilson's disease mutations and restoration of normal copper handling in animal models, supporting its potential as a curative therapy.
Technology BreadthAnalysts note Prime's mutation-agnostic prime editing approach may allow treatment of a broader patient pool and improve the therapy's commercial potential compared with mutation-specific solutions.
Bears Say
Market Positioning And SentimentAnalysts point to elevated short interest at about 21% of the float, which can amplify downside moves and signal meaningful investor skepticism.
Reimbursement And Pricing RiskAnalysts highlight that the high annual cost of the current standard of care, noted at over $300,000, may prompt intense payer scrutiny and complicate reimbursement and pricing for new gene-editing therapies.
Sector VolatilityAnalysts warn that recent high-profile deals and clinical setbacks have driven extreme volatility across the gene editing sector, increasing selling pressure on companies like Prime.
Prime Medicine, Inc. News
PRME FAQ
What was Prime Medicine, Inc.’s price range in the past 12 months?
Prime Medicine, Inc. lowest stock price was $1.11 and its highest was $6.94 in the past 12 months.
What is Prime Medicine, Inc.’s market cap?
Prime Medicine, Inc.’s market cap is $644.42M.
When is Prime Medicine, Inc.’s upcoming earnings report date?
Prime Medicine, Inc.’s upcoming earnings report date is Feb 27, 2026 which is in 17 days.
How were Prime Medicine, Inc.’s earnings last quarter?
Prime Medicine, Inc. released its earnings results on Nov 07, 2025. The company reported -$0.32 earnings per share for the quarter, missing the consensus estimate of -$0.253 by -$0.067.
Is Prime Medicine, Inc. overvalued?
According to Wall Street analysts Prime Medicine, Inc.’s price is currently Undervalued.
Does Prime Medicine, Inc. pay dividends?
Prime Medicine, Inc. pays a Quarterly dividend of $0.8 which represents an annual dividend yield of N/A. See more information on Prime Medicine, Inc. dividends here
What is Prime Medicine, Inc.’s EPS estimate?
Prime Medicine, Inc.’s EPS estimate is -0.25.
How many shares outstanding does Prime Medicine, Inc. have?
Prime Medicine, Inc. has 180,510,650 shares outstanding.
What happened to Prime Medicine, Inc.’s price movement after its last earnings report?
Prime Medicine, Inc. reported an EPS of -$0.32 in its last earnings report, missing expectations of -$0.253. Following the earnings report the stock price went down -8.852%.
Which hedge fund is a major shareholder of Prime Medicine, Inc.?
Currently, no hedge funds are holding shares in PRME
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Prime Medicine, Inc. Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$5.08 (42.30% Upside)
$5.08 (42.30% Upside)
Blogger Sentiment
Neutral
PRME Sentiment 50%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 13.2M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Neutral
Last 7 Days ▲ 0.2%
Last 30 Days ▼ 0.6%
Last 30 Days ▼ 0.6%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
41.66%
12-Months-Change
Fundamentals
Return on Equity
-112.34%
Trailing 12-Months
Asset Growth
15.69%
Trailing 12-Months
Company Description
Prime Medicine, Inc.
Prime Medicine, Inc., a biotechnology company, delivers genetic therapies to address diseases by deploying gene editing technology. It offers Prime Editors with a Prime Editor protein, comprising a fusion between a Cas protein and a reverse transcriptase enzyme; and a pegRNA, which targets the Prime Editor to a specific genomic location and provides a template for making the desired edit to the target DNA sequence. The company was incorporated in 2019 and is headquartered in Cambridge, Massachusetts.
PRME Stock 12 Month Forecast
Average Price Target
$5.08
▲(42.30% Upside)
Technical Analysis
Immatics
―
Relay Therapeutics
―
Taysha Gene Therapies
―
Sana Biotechnology
―
Upstream Bio, Inc.
―
Ownership Overview
Currently, No data available
---